The positive CDH17 ratios were 63.6% (7/11) for grade 2 and 56.5% (13/23) for grade 3 in the primary cancer specimens, and 86.7% (6/7) for grade 2 and 51.9% (14/27) for grade 3 in the LN metastasis specimens (Table 3). This evidence concerns the gene CDH17 and cancer.